ADIL Adial Pharmaceuticals Inc

Price (delayed)

$1.06

Market cap

$4.49M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.15

Enterprise value

-$537,804

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, ...

Highlights
Adial Pharmaceuticals's quick ratio has surged by 106% QoQ
Adial Pharmaceuticals's debt has plunged by 100% YoY
Adial Pharmaceuticals's net income has plunged by 70% from the previous quarter but it has increased by 32% YoY

Key stats

What are the main financial stats of ADIL
Market
Shares outstanding
4.23M
Market cap
$4.49M
Enterprise value
-$537,804
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.21
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$8.69M
EBITDA
-$8.71M
Free cash flow
-$6.13M
Per share
EPS
-$3.15
Free cash flow per share
-$2.08
Book value per share
$5.03
Revenue per share
$0
TBVPS
$2.26
Balance sheet
Total assets
$6.68M
Total liabilities
$562,731
Debt
$0
Equity
$6.12M
Working capital
$4.77M
Liquidity
Debt to equity
0
Current ratio
9.48
Quick ratio
8.93
Net debt/EBITDA
0.58
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-192.5%
Return on equity
-219.2%
Return on invested capital
-538.4%
Return on capital employed
-142%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ADIL stock price

How has the Adial Pharmaceuticals stock price performed over time
Intraday
-2.75%
1 week
-6.19%
1 month
-5.36%
1 year
-84.06%
YTD
-43.01%
QTD
-7.83%

Financial performance

How have Adial Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$6.46M
Net income
-$8.69M
Gross margin
N/A
Net margin
N/A
Adial Pharmaceuticals's net income has plunged by 70% from the previous quarter but it has increased by 32% YoY
The operating income rose by 39% year-on-year and by 6% since the previous quarter

Growth

What is Adial Pharmaceuticals's growth rate over time

Valuation

What is Adial Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.21
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 75% YoY and by 13% QoQ
The stock's price to book (P/B) is 95% less than its 5-year quarterly average of 4.6 and 79% less than its last 4 quarters average of 1.0
ADIL's equity is up by 50% QoQ

Efficiency

How efficient is Adial Pharmaceuticals business performance
The ROIC has soared by 98% YoY but it fell by 34% QoQ
ADIL's return on assets is down by 44% since the previous quarter and by 7% year-on-year
ADIL's ROE is up by 22% YoY but it is down by 20% QoQ

Dividends

What is ADIL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ADIL.

Financial health

How did Adial Pharmaceuticals financials performed over time
Adial Pharmaceuticals's quick ratio has surged by 106% QoQ
ADIL's current ratio has surged by 93% since the previous quarter
Adial Pharmaceuticals's debt is 100% less than its equity
Adial Pharmaceuticals's debt has plunged by 100% YoY
The debt to equity has dropped by 100% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.